Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
PMID 33354859
Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial
A) all generic cos were very low on their GLP1 forecast before the launch - a few 10s of crores at best in the 1st year eg A top co in India had a 10cr first yr sales forecast and is set to do a multiplier of that On top of that fewer than expected cos have launched B) online sales which is the biggest area of growth on GLP1s (pharmacies / Telehealth) doesnt get captured and so is direct sales
2024;47(Suppl 1):S1S308
Confirm general, clinical, and pharmacy support separately
US$ 23.34
US$ 28.22
US$ 26.08
US$ 29.38
US$ 26.66
